Abstract: Drug delivery across the blood-brain barrier (BBB) is af ormidable challenge for therapies targeting the central nervous system. Although BBB shuttle peptides enhance transport into the brain non-invasively,t heir application is partly limited by lability to proteases.T he present study proposes the use of cyclic peptides derived from venoms as an affordable way to circumvent this drawback. Apamin, aneurotoxinf rom bee venom, was minimized by reducing its complexity,t oxicity,a nd immunogenicity,w hile preserving brain targeting,a ctive transport, and protease resistance. Among the analogues designed, the monocyclic lactambridged peptidomimetic MiniAp-4 was the most permeable. This molecule is capable of translocating proteins and nanoparticles in ah uman-cell-based BBB model. Furthermore, MiniAp-4 can efficiently deliver ac argo across the BBB into the brain parenchyma of mice.
The incidence of brain diseases is increasing mainly because of population aging.Unfortunately,most molecules intended for therapy and with high in vitro efficiency fail to reach their targets because they are unable to cross the blood-brain barrier (BBB) in adequate amounts. [1] One of the most promising non-invasive strategies under investigation for drug delivery to the central nervous system (CNS) is the use of BBB shuttles. [2] These vectors are able to enhance the passage of compounds across the BBB without altering its integrity.In the last few years,m uch research effort has been devoted to identifying peptide shuttles because these molecules are more economical, less immunogenic,a nd have higher chemical versatility than large proteins,such as Tr ojan horse antibodies. Nevertheless,animportant drawback of existing sequences is their high lability to serum proteases.W ea nd others have recently shown that peptides with reversed sequences and damino acids (retro-enantio approach) can be more efficient carriers than their l-counterparts. [3] Nonetheless,this strategy is relatively costly and may decrease the affinity of the peptide for the receptor that mediates its transport. Away to circumvent these drawbacks could be the use of natural cyclic peptides targeting the CNS,s uch as those found in venoms. However,a ni nconvenience of using these compounds as BBB shuttles is their high toxicity.I np articular,t he bicyclic peptide apamin, found in bee venom, crosses the BBB and blocks calcium-mediated potassium channels. [4] Despite the proven CNS-targeting capacity of apamin, [5] the extended application of this molecule has been limited by its toxicity, high immunogenicity, [6] and relatively complex structure.T wo years ago,w er eported that the replacement of arginines by ornithines yielded anon-toxic apamin analogue that is able to cross atight monolayer of bovine endothelial cells mimicking the BBB. [7] Our present study aimed to obtain all-l-proteaseresistant shuttles by minimizing apamin, while reducing its toxicity and immunogenicity.F urthermore,w es tudied the ability of these shuttles to carry large cargoes in ahuman-cellbased BBB model and to reach the mouse brain parenchyma.
To simplify the structure of apamin, we first synthesized the native peptide and anon-reported analogue that does not contain the main residues responsible for its toxicity (MiniAp-1;F igure 1a). We assayed both compounds in ab ovine-cell-based BBB model and found that the permeability of MiniAp-1 was 60 %h igher than that of apamin (Figure 1b ;s ee also the Supporting Information, Table S2 ). Lucifer yellow was used as an integrity marker. [8] Thes trong inhibition of MiniAp-1 transcytosis by ac hange in temperature or the addition of sodium azide ( Figure S2 a) indicated that the shuttle was transported mainly through an active mechanism. Next, we showed that this analogue was capable of carrying small cargoes,s uch as dopamine,c arboxyfluorescein (cF), sulforhodamine B, and an amyloid b-sheet breaker peptide (Figure S2 b) . These results encouraged us to further dissect the structure and prepare minimized derivatives based on the loop between Cys-3 and Cys-11. We first synthesized al inear version (MiniAp-2), which was transported less efficiently than MiniAp-1 and readily degraded by serum proteases (Figure 1c ). We then prepared am onocyclic analogue by connecting Cys-3 and Cys-11 (MiniAp-3). This peptide showed permeability values similar to those of MiniAp-1, and was over 30 times more resistant to serum proteases than the linear version. Finally,byswitching the disulfide to al actam bridge,w eo btained MiniAp-4 ( Figure 1d ). Remarkably,t he permeability of the latter was 50 %h igher than that of MiniAp-3, which could be attributable to its impressive resistance to serum proteases (t 1/2 = 24 h). Aiming to further explain the differences in BBB transport between the analogues,westudied their conformational preferences.T he a-helical structure of MiniAp-1, typical of apamin, [9] was confirmed by circular dichroism (CD;F igure 1e)and by the following NMR parameters:
1 H a and 13 C a secondary chemical shifts,N OE patterns,t he NH temperature coefficients,and the 3 J aNH coupling constants (Tables S3,  S4 and Figure S5 ). Thet hree-dimensional structures of this analogue were determined by simulated annealing methods (Figure 1fand Table S5 ), whereas the other peptides were too flexible to provide ar eliable model. In particular, the CD spectrum and the NMR parameters of the linear analogue (MiniAp-2) showed ac lear random coil behavior. Although the structural data for MiniAp-3 and MiniAp-4 suggested that they had no defined secondary structure,alarger amide proton chemical shift dispersion (Figure 1g )a nd notable differences in the 13 C a chemical shifts (Figure 1h )i ndicated that they had lower conformational flexibility than MiniAp-2. Most remarkably,w hereas the linear analogue showed a1 :9 cis/trans Ala-Pro conformer population ratio like the bicyclic peptides (apamin and MiniAp-1), the two monocyclic derivatives showed aratio of 1:1. Thehigher preference for the cis Ala-Pro rotamer in MiniAp-4 with respect to MiniAp-1 could partly account for the difference in permeability between the two analogues with highest resistance to proteases.
We next studied the toxicity and immunogenicity of MiniAp-1 and MiniAp-4. Ar emarkable decrease in acute toxicity for both analogues was confirmed through intravenous injection in mice at ad ose 24 times the LD 50 of apamin [10] causing no observable symptoms during 24 hours. Regarding immunogenicity,i natwelve week study,w e confirmed that apamin was highly immunogenic,e ven when injected at 25 mgd oses to avoid toxicity.H owever,a lthough MiniAp-1 generated six-fold fewer IgGs than apamin, it was still relatively virulent ( Figure 2) . Conversely,t he amount of antibodies generated by MiniAp-4 was at least three orders of magnitude lower than that produced by apamin. 
Angewandte Chemie

Communications
Taking into account the results from the permeability, stability,a nd immunogenicity experiments,w ed etermined that MiniAp-4 was the lead mini-apamin shuttle candidate.T o assess whether the peptide was suitable to transport large cargoes,westudied the internalization mechanism of the cFMiniAp-4 construct in bEnd.3 cells using inhibitors of the two main pathways reported to be involved in transcytosis.C ell uptake was not affected by chlorpromazine,w hich inhibits internalization through clathrin-coated pits, [11] but was reduced by filipin ( Figure S3 ), which interferes with caveolaemediated endocytosis. [12] At this point, we switched to amore relevant human-cellbased BBB model, which has recently been developed to study transcytosisa nd has good correlation with human clinical data. [13] In the new model, MiniAp-4 showed greater permeability than in the bovine one (Table S2 ). This observation is highly relevant for the potential translation of the shuttle to humans as it suggests that the translocation mechanism is also operating in human cells.T he ability of MiniAp-4 to carry covalently attached macromolecules and nanoparticles was first confirmed by a1.6-fold increase in the transport of GFP (Figure 3a,b) . Importantly,as crambled version of the peptide did improve neither the permeability nor the cell uptake of GFP ( Figure S9 ). These results underscore the relevance of the residue sequence in MiniAp-4 to mediate translocation and would be consistent with ar eceptor-mediated transcytosis mechanism. Furthermore,atwofold transport increase was observed for far-red imaging quantum dots (Qdot-605). This enhancement is similar to those achieved with similar cargoes using other peptide BBB shuttles. [14] However,i nc ontrast to most reported shuttles,MiniAp-4 is small and resistant to protease degradation, properties that are considerable advantages for production and in vivo efficiency,r espectively.F inally,w e assayed 12 nm gold nanoparticles (AuNPs) because of their potential therapeutic applications. [15] In this case,the increase was even more pronounced (over 20-fold), probably because of the low permeability of the cargo alone and the higher functionalization (Figure 3a) .
After finding that MiniAp-4 transports various compounds in the human BBB model, we demonstrated that it was capable of delivering acargo in mice.Brain accumulation of the peptide linked to cyanine 5.5 (Cy5.5-MiniAp-4) was compared to the same fluorophore capped with cysteamine (Cy5.5-CA; Figure S10 ). Upon intravenous injection of the compounds,a4.3-fold increase of fluorescence in the brain region was observed (Figure 3c) . Theenhancement provided by MiniAp-4 was even higher (7.6-fold) when measured in the excised brains upon perfusion with PBS 1hafter injection and was significantly selective for the brain compared to the lungs, heart, and spleen (Figures 3d and S11) .
Finally,u sing fluorescence microscopy,w eo bserved that the targeted fluorophore not only colocalized with capillaries but also was found in the form of aggregates in the brain parenchyma, unlike the cysteamine version (Figure 3e) . The aggregates were found inside neurons,ahighly relevant observation for the potential treatment of neurodegenerative diseases,a nd only colocalized to as mall extent with ag lial marker ( Figure S12 ).
In summary,w eh ave shown that MiniAp-4, am inimized and more permeable peptidomimetic version of apamin, is resistant to proteases and able to efficiently deliver diverse cargoes across the blood-brain barrier in ahuman-cell-based model and also in vivo.F urthermore,t his shuttle has ar emarkable brain-targeting capacity and is considerably less toxic and immunogenic than the native peptide.
